Moderna Analyst: Unrealistic COVID-19 Vaccine Expectations Create Unfavorable Setup

Coronavirus vaccine developer Moderna Inc's MRNA stock was moving lower Monday after a downgrade from BofA Securities. 

The Moderna Analyst: Geoff Meacham downgraded Moderna shares from Neutral to Underperform and maintained a $150 price target.

The Moderna Thesis: Moderna shares have seen an extended rally, rising 425% in 2020 and an incremental 66% year-to-date, Meacham said in a Monday note.

The shares have now catapulted to levels that are increasingly difficult to justify on a fundamental basis, the analyst said. 

The gains have come despite rival vaccine candidates from Novavax, Inc. NVAX and Johnson & Johnson JNJ moving toward approval by the FDA in the near term, he said. 

The Moderna and Pfizer Inc. PFE-BioNTech SE – ADR BNTX vaccines may have best-in-class efficacy, but the volume and lower price points from Novavax, J&J, AstraZeneca plc AZN and others will likely affect cumulative sales expectations for Moderna, Meacham said. 

Related Link: Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates

For supporting a valuation over $180, Moderna should generate more than $85 million in cumulative COVID-19 vaccine sales, the analyst said, adding that this is reflected in the share price at current levels.

BofA's $150 price target already implies significant mRNA-1273 upside at $47 billion over the next 10 years, concentrated primarily in 2021-2023, he said. 

Additionally, consensus expectations for Moderna's vaccine sales are unrealistic, Meacham said. 

"These factors, together with a pipeline that is still too early to compensate for declining vaccine sales (CMV launch in 2024e), creates an unfavorable setup for MRNA shares." 

MRNA Price Action: At last check, Moderna shares were slipping 8.99% to $157.60. 

Related Link: The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechDowngradesHealth CareReiterationAnalyst RatingsMoversTrading IdeasGeneralBofA SecuritiesCoronavirusCovid-19Geoff Meachamvaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!